A Placebo Controlled Study of Homeopathic Treatment of Children and Youth With ADHD
NCT02086864 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151
Last updated 2024-05-14
Summary
Attention Deficit Hyperactivity Disorder (ADHD) is a developmental disorder that presents during childhood, with at least some symptoms causing impairment before the age of seven. It is characterized by developmentally inappropriate levels of inattention and/or hyperactive-impulsive behavior, with significant impairment occurring in at least two settings. It affects approximately 5.2 million children in the United States. Homeopathic treatment has been shown to be a promising intervention for ADHD, however the reasons for that effectiveness is unclear. Specifically, it is unclear whether improvement is due to the homeopathic medicine, the consultative process, or other non-specific effects.
This study has 3 primary objectives: 1. to determine if there are any specific effects of homeopathic medicines in the treatment of ADHD, 2. to determine if there any specific effects the homeopathic consultation alone in the treatment of ADHD, and 3. to determine if there is an overall effect of homeopathic treatment (homeopathic medicines plus consultation) in the treatment of ADHD.
This is a three arm study. Participants will be randomized to one of three arms:
Arm 1 (Verum group): a treatment arm where the participant will receive homeopathic consultation plus a homeopathic remedy Arm 2 (Placebo group): a treatment arm where the participant will receive homeopathic consultation plus a placebo remedy Arm 3 (Usual care group): participants will continue with usual care and will not receive homeopathic treatment as part of the study.
Participants enrolled in this study, regardless of which study Arm they are in, may continue with all conventional medications or any other aspect of their current standard of care they are taking as recommended by their usual physician (so long as they are on a stable dose of the conventional ADHD medication for at least 6 weeks prior to beginning the trial). They may also continue to attend regularly scheduled visits with their own health care practitioner(s).
Participants may also start, stop or change the dose of any therapy (including conventional medications) during the study and are asked to report the change to the study team. Thus, the placebo group participants are not different than other participants, except that they will have a homeopathic consultation and a placebo remedy. The use of placebo is specific to homeopathic treatment, to allow for double-blinding, which is recognized to reduce study bias.
Prior to enrolling in the study, those considering participation will undergo a full assessment by a psychiatrist with a specialty in child and youth mental health. This assessment confirms the diagnosis and screens for inclusion/exclusion study criteria. At the same time, the psychiatrist recommends evidence-based therapies to clients including conventional medication. The psychiatrist does not directly treat the client. If medication is recommended and the clients wish to pursue it with their regular physician, they would still be able to enroll in the study if they wanted to, after six weeks of reaching a stable dose.
This study will help our understanding of the treatment process and whether different elements of the intervention have greater or lesser effects.
This study is a follow-up to an open label pilot study of the homeopathic treatment of ADHD using the same study team. Sample size was calculated based on the results of that study.
Conditions
- Attention Deficit Hyperactivity Disorder
Interventions
- DRUG
-
lactose/sucrose granule (Individualized homeopathic medicine treatment)
The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
- DRUG
-
Placebo lactose/sucrose pill
- BEHAVIORAL
-
Homeopathic consultation
Sponsors & Collaborators
-
Lotte & John Hecht Memorial Foundation
collaborator OTHER -
Centre for Addiction and Mental Health
collaborator OTHER -
University of Toronto
lead OTHER
Principal Investigators
-
Heather Boon, PhD · University of Toronto
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 6 Years
- Max Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-03-31
- Primary Completion
- 2021-03-31
- Completion
- 2023-08-31
Countries
- Canada
Study Locations
More Related Trials
-
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
NCT00191906 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy
NCT00485550 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
NCT00607919 ·Status: COMPLETED ·Phase: PHASE4
-
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
NCT00380692 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study
NCT06841666 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00498173 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
NCT00510276 ·Status: COMPLETED ·Phase: PHASE4
-
Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents
NCT00191542 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00546910 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Continuous Symptom Treatment of ADHD
NCT00486122 ·Status: COMPLETED ·Phase: PHASE4
-
Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder
NCT00142961 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
NCT00191633 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
NCT00191048 ·Status: COMPLETED ·Phase: PHASE4
-
A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder
NCT00190931 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00190775 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Atomoxetine Treatment in Humans
NCT00611936 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents
NCT00252278 ·Status: UNKNOWN ·Phase: PHASE4
-
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
NCT00218322 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
NCT00386581 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00320528 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)
NCT00191386 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD
NCT00486083 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
NCT00190736 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents
NCT00566371 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
NCT00406354 ·Status: COMPLETED ·Phase: PHASE4